Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction
Publication date
2019-02-01
Authors
Griesinger, Georg
Tournaye, Herman
Macklon, Nicholas
Petraglia, Felice
Arck, Petra
Blockeel, Christophe
van Amsterdam, Peter
Pexman-Fieth, Claire
Fauser, Bart CJM
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.
Keywords
Duphaston, Dydrogesterone, In-vitro fertilization, Luteal phase support, Pharmacological profile, Progesterone, Dydrogesterone/therapeutic use, Progestins/therapeutic use, Humans, Luteal Phase/drug effects, Reproductive Techniques, Assisted, Pregnancy, Female, Pregnancy Rate, Taverne, Review, Journal Article
Citation
Griesinger, G, Tournaye, H, Macklon, N, Petraglia, F, Arck, P, Blockeel, C, van Amsterdam, P, Pexman-Fieth, C & Fauser, B CJM 2019, 'Dydrogesterone : pharmacological profile and mechanism of action as luteal phase support in assisted reproduction', Reproductive Biomedicine Online, vol. 38, no. 2, pp. 249-259. https://doi.org/10.1016/j.rbmo.2018.11.017